trending Market Intelligence /marketintelligence/en/news-insights/trending/f_OWWMkdpWv8J-suII5lXA2 content esgSubNav
In This List

Synthetic Biologics CFO to lead company on interim basis

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Synthetic Biologics CFO to lead company on interim basis

Synthetic Biologics Inc. said Jeff Riley resigned as CEO and board director for personal reasons.

Synthetic's CFO, Steve Shallcross, will take over CEO duties on an interim basis.